Thursday, 26 February 2026
An expert in Clinical Trials from the 糖心原创 is part of an international team of experts who have come together to enhance clinical trial conduct and reporting.
Paediatric randomised controlled trials provide evidence for patients, families, researchers, clinicians, regulators, funders, policymakers and other interest-holders to inform decisions regarding healthcare interventions and improve outcomes for patients and their families.
The BMJ has teamed up with leading paediatric journals JAMA Pediatrics and The Lancet Child & Adolescent Health to co-publish two papers that will enhance trial conduct and reporting to improve the health of young patients and their families.
The papers provide essential checklist items for researchers to include in clinical trial protocols and reports aimed at enhancing the usefulness, and impact of paediatric randomised controlled trials.
For example, what is the rationale for undertaking the trial in children/adolescents and how will participants’ consent be obtained and their confidentiality respected? How will age or development-related differences in treatment effects be addressed, and what impact will trial participation have on the child/adolescent’s daily life?
The paper authors say this new guidance will strengthen the quality and safety of the paediatric evidence base, improve health outcomes of children and adolescents, and reduce research and resource waste. Importantly, both guidelines were developed in partnership with young people (ages 10-24 years) and family caregivers.
Professor Ed Juszczak, Professor of Clinical Trials and Statistics in Medicine, Nottingham Clinical Trials Unit, is part of the international collaboration that has produced these new reporting guidelines plus associated Explanation and Elaboration papers.
Ed has a long track record in perinatal clinical trials and has led or co-authored several other similar reporting guidelines. His role on the international steering committee included contributing to discussions around the creation of a long list of prospective items, shortlisting, reviewing the results of the Delphi processes, sourcing examples of good reporting, and dissemination.
While there are many guidelines for the reporting of clinical trials, none up until now, have addressed the unique aspects specific to research involving children and young people. These guidelines should lead to clinical trials that are better designed and conducted, and importantly, reported more transparently. Ultimately this will lead to improved care and outcomes for children, young people and their families in the future.鈥�
Story credits
The links to the papers can be found below:
Enhancing the reporting and impact of paediatric randomised trials: CONSORT-Children and Adolescents (CONSORT-C) 2026 extension
Enhancing the reporting and usefulness of paediatric randomised trial protocols: SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension
CONSORT-C 2026 Explanation and Elaboration: Recommendations for enhancing the reporting and impact of paediatric randomised trials
SPIRIT-C 2026 Explanation and Elaboration: Recommendations for enhancing the reporting and usefulness of paediatric randomised trial protocols
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.